Irrespective of HFrEF duration ⏱️
✅ ARNI works
✅ BB works
✅ MRA works
✅ SGLT2i works
To modify HF disease progression and ⬇️⬇️⬇️⬇️ ☠️/HF 🏨
Clinical benefits are additive, incremental, cumulative
Quantification of the lives that could be saved and worsened HF events that could be prevented if there was optimal implementation of SGLT inhibitors for HF globally
No time to wait
Benefits>>Potential Risks
https://t.co/FsHelNUClu
GDMT for HF
Immediate vs delayed
Quadruple vs double or triple
Comprehensive vs incomplete
Target dosing vs suboptimal
The difference between
Optimal clinical outcomes vs events that could have been prevented but were unfortunately not
Wow! An SGLT2i is sold at $47.85!!!! (shipping included) 🥳🍾🎉🤑💸
That is 8% of the going price of empagliflozin or dapagliflozin!!
Caveat: Only indication in T2DM (not HF or CKD)
https://t.co/e17wlZfHM5
@ChristosArgyrop@JonathanDavisHF@AndrewJSauer@hvanspall@dranulala
Join us July 31 from 4:30 - 5:30 PM PT for our webinar w/ @Intermountain,Transforming Heart Failure Care Delivery. Learn how our partnership affects heart failure care & improves patients' quality of life.
@Ashul@KismetRasmu@tomstanis
Register today:
https://t.co/TQJarnB3pr
“It raises interesting questions about autonomy, and the source of commands. You’re continuing to blur the philosophical boundary between what’s the brain and what’s the technology.”
https://t.co/niHiULvYfa
"As we've gotten to know the Story Health team, we've been highly impressed with their pioneering approach to care that focuses on a patient’s journey outside of the doctor’s office, where keeping folks healthy through proactive interventions is key." https://t.co/PVgBxOeynM
“In chronic condition management, we have the unprecedented opportunity to leverage AI, remote care, & patient engagement apps to improve population health at scale; bringing care to those who need it most.”@ashul@MedEconomics#medtwitter#CardioTwitter
https://t.co/mPXufG6AkR
SBP ⬇️ 23 mmHg
⬇️⬇️ CV events
Effectiveness of a non-physician community health-care provider-led intensive BP intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial - The Lancet https://t.co/0mAzGHHk7O
"A key point conveyed in this analysis is that these patients need all the help they can get with maximally improving their clinical outcomes." @SJGreene_md@MKIttlesonMD#HFrEF https://t.co/2AeMtVkhNU
If the dermatologist can start spironolactone for acne without even checking labs,
…perhaps you can stop discontinuing my patients’ spiro for K = 4.5
I’m here all day.
@AHajduczok@DrMarthaGulati@RyanTedfordMD@ShelleyZieroth
Our digital hybrid care model that couples AI technology with real health providers is transforming how complex patient care is delivered. @StoryHealthAI is excited to partner with @Intermountain in this new endeavor.
“Story Health offers a novel way to improve how medications are optimized using an electronic monitoring platform coupled with health coaches to put the clinical team's plan in place."
- @KismetRasmu, NP of @Intermountain
Read the full press release: https://t.co/g2svOQpAYS
We need to be rethinking how we escalate therapy for patients with afib.
Progression of Atrial Fibrillation after Cryoablation or Drug Therapy | NEJM https://t.co/MuO065k01k
Honestly I'm suprised it took that long to diagnose...
The Washington Post: It took decades to diagnose the cause of her fainting episodes.
https://t.co/P8mjdC2uze
Doctors don't have sight of you between visits & gaps in #heartfailure care are a fundamental issue. We wanted to be the solution - change episodic care to a continuous digital hybrid model. Thank you Mike Moore & Bleeding Edge of Digital Health Podcast.
https://t.co/xThwszzaAo